Parabilis Medicines adds oncology veteran Craig Tendler to board

Parabilis Medicines (Nasdaq: PBLS) announced on August 25, 2026 that its Board of Directors had appointed Craig L. Tendler, M.D. as a new member. Dr. Tendler previously led both clinical development and medical affairs for oncology at Johnson & Johnson, and has served as a scientific advisor to Parabilis, a role he will continue alongside his board duties.¹

According to the company, Dr. Tendler has more than 30 years of experience in oncology drug development and medical affairs, spent two decades at Johnson & Johnson in roles spanning clinical development, medical affairs and business development, and most recently served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology.¹ The release states that while at J&J he contributed to more than 30 oncology regulatory approvals spanning prostate cancer, hematologic malignancies, lung cancer and bladder cancer, along with 13 FDA Breakthrough Therapy designations and approvals for 15 New Molecular Entities.¹ He is also credited with involvement in J&J's acquisitions of Cougar Biotechnology, Aragon Pharmaceuticals and Taris Biomedical, as well as partnerships with Legend Biotech, Pharmacyclics and Genmab.¹

Per the accompanying Form 8-K, the board increased its size to nine directors on August 22, 2026 and appointed Tendler to fill the new seat as a Class II director, with a term running until the 2028 annual meeting.¹ The board determined he is independent under Nasdaq listing standards and also named him to the Science & Technology Committee.¹

On compensation, Tendler received a stock option for 20,294 shares at an exercise price of $39.36 per share, vesting monthly over three years, contingent on continued board service.¹ He will also receive an annual retainer of $40,000 for board service and $7,500 for committee service, paid quarterly.¹